Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
about
DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerIdentification of therapeutic targets applicable to clinical strategies in ovarian cancerModel-based contextualization of in vitro toxicity data quantitatively predicts in vivo drug response in patients.All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damageConserved molecular mechanisms underlying the effects of small molecule xenobiotic chemotherapeutics on cells.Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.Inhibitory effects of bevacizumab monoclonal antibodies in combination with chemotherapy in different time sequences on a human gastric carcinoma cell line.Targeting the ATR-CHK1 Axis in Cancer TherapyThe cell cycle checkpoint inhibitors in the treatment of leukemias.BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).BRCA1 or CDK12 loss sensitizes cells to CHK1 inhibitors.Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells.A lethal synergy induced by phellinus linteus and camptothecin11 in colon cancer cells.miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer.DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cellsCariprazine, A Dopamine D₂/D₃ Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
P2860
Q26776513-CAD52BBF-CCB5-4D69-8084-1F2CD3ADABC9Q28829029-233E00F5-74C4-48EA-926A-BDAEE1138DD5Q30838395-FDA132B9-BE83-4222-AACC-EA3AA5E77A4FQ35884399-54E512AD-013D-4CF4-9725-2AD2862EBB5BQ38719813-912E66E8-6689-47BE-978F-7D9439CF63E4Q38756843-2E754116-E118-4588-9F70-FBD4628B1C6FQ38761344-F12AC0FD-94C4-449B-AEFC-A382E11CC4C4Q38817102-D421428E-D1C8-4D34-9F4F-ECBAD707F9B6Q38868502-F8AD1029-FC9D-4801-9BB9-04ED1A0F4208Q41612803-899E45EF-E8CD-4B4B-B20F-4AD8289EB2F9Q47660928-A7B890E7-F9DA-450E-98C1-8B43BA291821Q48534871-043A4DC8-109C-4C38-BAE2-47CBFBEB241FQ49479651-6D584B97-5FF6-44AD-9F51-37569AC58965Q49787504-E4DAC7FF-FCAD-4871-9F9A-F4C6C54E8B88Q53695419-8B88BD02-8F95-4A21-96EB-C2703072E06DQ58749027-3229084E-321C-42F8-9B4F-53C916A87BF4Q58764275-AF896A32-A181-4C81-BC1D-EE43AA295E6B
P2860
Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Topotecan synergizes with CHEK ...... tosis in ovarian cancer cells.
@ast
Topotecan synergizes with CHEK ...... tosis in ovarian cancer cells.
@en
type
label
Topotecan synergizes with CHEK ...... tosis in ovarian cancer cells.
@ast
Topotecan synergizes with CHEK ...... tosis in ovarian cancer cells.
@en
prefLabel
Topotecan synergizes with CHEK ...... tosis in ovarian cancer cells.
@ast
Topotecan synergizes with CHEK ...... tosis in ovarian cancer cells.
@en
P2093
P2860
P1433
P1476
Topotecan synergizes with CHEK ...... tosis in ovarian cancer cells.
@en
P2093
Christina M Annunziata
Jana James
Marianne K Kim
P2860
P2888
P356
10.1186/S12885-015-1231-Z
P407
P577
2015-03-28T00:00:00Z
P5875
P6179
1014779490